* Akoya Biosciences Inc AKYA.OQ AKYA.O is expected
to show a
rise in quarterly revenue when it reports results on November
7.
* The Marlborough Massachusetts-based company is expected
to
report a 31.0% increase in revenue to $17.658 million from
$13.48 million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Akoya Biosciences
Inc is
for a loss of 44 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Akoya
Biosciences
Inc is $19, above its last closing price of $13.82.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.39 -0.37 -0.47 Missed -26.3
Mar. 31 2022 -0.40 -0.39 -0.44 Missed -13.5
Dec. 31 2021 -0.29 -0.31 -0.47 Missed -51.6
Sep. 30 2021 -0.26 -0.26 -0.31 Missed -17
Jun. -0.23 -0.23 -0.20 Beat 13
30 2021
Mar. 31 2021 -0.17 -0.17 -3.54 Missed -2,013
.4
This summary was machine generated November 5 at 03:03 GMT. All
figures in US dollars unless otherwise stated